CRNX Crinetics Pharmaceuticals Inc

Price (delayed)

$16.19

Market cap

$608.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.44

Enterprise value

$506.35M

Sector: Healthcare
Industry: Biotechnology

Highlights

The debt has declined by 19% year-on-year and by 6% since the previous quarter
The quick ratio has increased by 40% YoY but it has decreased by 10% QoQ
CRNX's equity is up by 38% year-on-year but it is down by 12% since the previous quarter
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
CRNX's gross profit has plunged by 100% from the previous quarter and by 100% YoY

Key stats

What are the main financial stats of CRNX
Market
Shares outstanding
37.59M
Market cap
$608.64M
Enterprise value
$506.35M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.58
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$79.35M
EBITDA
-$78.12M
Free cash flow
-$70.11M
Per share
EPS
-$2.44
Free cash flow per share
-$2.12
Book value per share
$4.53
Revenue per share
$0
TBVPS
$4.95
Balance sheet
Total assets
$163.55M
Total liabilities
$14.07M
Debt
$3.79M
Equity
$149.48M
Working capital
$147.54M
Liquidity
Debt to equity
0.03
Current ratio
15.37
Quick ratio
14.73
Net debt/EBITDA
1.31
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-41.5%
Return on equity
-44.8%
Return on invested capital
-121.1%
Return on capital employed
-51.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRNX stock price

How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
1.82%
1 week
-4.54%
1 month
-1.4%
1 year
-14.88%
YTD
14.74%
QTD
5.96%

Financial performance

How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$80.09M
Net income
-$79.35M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
CRNX's gross profit has plunged by 100% from the previous quarter and by 100% YoY
CRNX's net income is down by 35% year-on-year and by 8% since the previous quarter
CRNX's operating income is down by 30% YoY and by 7% from the previous quarter

Growth

What is Crinetics Pharmaceuticals's growth rate over time

Valuation

What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.58
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CRNX's equity is up by 38% year-on-year but it is down by 12% since the previous quarter
CRNX's P/B is 21% above its last 4 quarters average of 2.9
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is Crinetics Pharmaceuticals business performance
The return on invested capital has dropped by 63% year-on-year and by 14% since the previous quarter
The company's return on equity rose by 5% YoY
The ROA has increased by 2.6% YoY

Dividends

What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRNX.

Financial health

How did Crinetics Pharmaceuticals financials performed over time
The current ratio has grown by 41% YoY but it has contracted by 9% from the previous quarter
The quick ratio has increased by 40% YoY but it has decreased by 10% QoQ
The debt is 97% smaller than the equity
CRNX's debt to equity has surged by 50% since the previous quarter but it is down by 25% year-on-year
CRNX's equity is up by 38% year-on-year but it is down by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.